Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T63512 Target Info
Target Name Extracellular lysophospholipase D (E-NPP2)
Synonyms LysoPLD; Ectonucleotide pyrophosphatase/phosphodiesterase family member 2; E-NPP 2; Autotaxin; ATX
Target Type Clinical trial Target
Gene Name ENPP2
Biochemical Class Phosphoric diester hydrolase
UniProt ID
ENPP2_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2015162558
Title Autotaxin Inhibitors.
Abstract The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition.
Applicant(s) Furminger
Representative Drug(s) D0J5GC Drug Info N.A. Click to Show More [1]
2 D0NG8Q Drug Info N.A. [1]
Patent ID WO2015008230
Title Autotaxin Inhibitors Comprising A Heteroaromatic Ring-Benzyl-Amide-Cycle Core.
Abstract The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
Applicant(s) Novartis Ag
Representative Drug(s) D04TUG Drug Info N.A. Click to Show More [1]
2 D0FN8Y Drug Info N.A. [1]
Patent ID WO2014152725
Title S1P and/or Atx Modulating Agents.
Abstract Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX). Formula (1).
Applicant(s) Biogen Ma Inc
Representative Drug(s) D0B7KP Drug Info N.A. Click to Show More [1]
2 D0F7NL Drug Info N.A. [1]
Patent ID WO2014097151
Title Autotaxin Inhibitors.
Abstract The present invention relates to novel compounds of formula (I) (I) that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition.
Applicant(s) Novartis Ag
Representative Drug(s) D0J5GC Drug Info N.A. Click to Show More [1]
2 D0NG8Q Drug Info N.A. [1]
Patent ID WO2014081752
Title S1P and/or Atx Modulating Agents.
Abstract Compounds of formula (I) wherein: X is -0-, -S(0)r-, -CH2-, or -NR-, wherein r is 0, 1, or 2; X 1, X2, and X5 are each independently CR7 or N; one of X3 or X4 is C and is attached by a single bond to -L-, and the other is CR7 or N, provided that no more than three of X1, X2, X3, X or X5 are N; Ring A is monocyclic C5-6scycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or 0; wherein Ring A is further optionally substituted with from 1 to 3 R4; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, -0-, -NR-, -S(0)n-, -CH2-,or -C(O)-, wherein n is 0, 1, or 2; 1 2 L1 is an C1-8alkylene, C3-scycloalkylene, -CH2-L2 -, or a 3- to 8- membered heterocyclylene comprising 1 to 5; R1 is C6-20alkyl or a monocyclic C3-8cycloalkyl; wherein said C3-8cycloalkyl is substituted with at least one R6 and may be optionally substituted with from 1 to 5 additional R6 substituents, wherein R6 for each occurrence is independently selected; and R2 is -C(0)OR3, -C(0)N(R3)-S(0)2R3, -S(0)2OR3, -C(0)NHC(0) R3, -Si(0)OH, - B(OH)2, -N(R3)S(0)2R3, -S(0)2N(R3)2, -O-P(O) (OR3)2, or -P(0)(OR3)2, -CN, - S(0)2NHC(0)R3, -C(0)NHS(0)2R3, - C(0)NHOH, -C(0)NHCN, -CH(CF3)OH, -C(CF3)2OH, or a selected heteroaryl or heterocyclyl; and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
Applicant(s) Biogen Ma Inc
Representative Drug(s) D0PI2I Drug Info N.A. Click to Show More [1]
2 D0WD8Z Drug Info N.A. [1]
3 D0WL5E Drug Info N.A. [1]
Patent ID WO2015188051
Title Atx Modulating Agents.
Abstract Compounds of formula (I) can modulate the activity of autotaxin (ATX).
Applicant(s) Biogen Ma Inc
Representative Drug(s) D06ZAE Drug Info IC50 < 100 nM [1]
Patent ID WO2015163435
Title Novel 2-Amino-Pyridine and 2-Amino-Pyrimidine Derivatives and Medicinal Use Thereof.
Abstract Provided are compounds that exhibit an excellent autotaxin (ATX) inhibitory effect, etc. and are efficacious as a prophylactic or therapeutic agent for diseases in which ATX participates. Compounds represented by general formula (I) [wherein each symbol is as defined in the description] have an excellent ATX inhibitory effect and are useful as a prophylactic or therapeutic agent for diseases in which ATX participates.
Applicant(s) Mitsubishi Tanabe Pharma Corporation
Representative Drug(s) D0GA6X Drug Info IC50 = 2 nM [1]
Patent ID WO2015077502
Title Tetracyclic Autotaxin Inhibitors.
Abstract Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
Applicant(s) Pharmakea, Inc
Representative Drug(s) D02FWT Drug Info IC50 < 500 nM [1]
Patent ID WO2014168824
Title Dihydropyrido Pyrimidine Compounds As Autotaxin Inhibitors.
Abstract The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis.
Applicant(s) Eli Lilly and Company
Representative Drug(s) D0FO4C Drug Info IC50 < 1.7 nM [1]
Patent ID WO2014110000
Title Pyrido- or Pyrrolo-Fused Pyrimidine Derivatives As Autotaxin Inhibitors for Treating Pain.
Abstract The present invention provides compounds of the Formula I: [Formula should be inserted here] wherein X is a bond or CH2; R is selected from the group consisting of [Formula should be inserted here] R1 and R2 are each independently selected from the group consisting of CH and N; R3 is H or CH3; R4 is H or CH3; L is selected from the group consisting of -0(CH2)3-, -C(0)NH(CH2)2-, -CH2C(0)NH(CH2)2-, -(CH2)3N(C(0)CH3)CH2-, -(CH2)2N(C(0)CH3)CH2-, -(CH2)3NH-, (CH2)2OCH2-, -(CH2)4-, -(CH2)2NHCH2-, -(CH2)30-, and -CH20(CH2)2-; pharmaceutically acceptable salt thereof. Compounds of this invention are autotaxin inhibitors.
Applicant(s) Eli Lilly and Company
Representative Drug(s) D02BGU Drug Info IC50 < 1.7 nM [1]
Patent ID WO2013054185
Title Pyrimidine and Pyridine Derivatives Useful In Therapy.
Abstract The invention provides compounds of formula (I), wherein one of X, Y and Z represents N and the other two represent CH, or X=Y-Z represents N=CH-N; W represents a CI-6 alkylene group which may be straight or branched; R1 represents H, phenyl, naphthyl, heteroaryl1, heterocyclyl1 or C3-6 cycloalkyl; wherein each phenyl, naphthyl, heteroaryl', heterocyclyl1 and C3-6 cycloalkyl group is optionally substituted, and wherein each phenyl, naphthyl, heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl group is optionally fused to a 5- or 6-membered heteroaromatic or heterocyclic ring containing from 1 to 3 heteroatoms (selected from N, O and S); and each heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl group is optionally fused to a benzene ring; m is 1 or 2; n is 0, 1 or 2; A is C=O or SO2; V represents a bond or C1-8 alkylene which may be straight or branched; R2 represents H, -S-(C1-6 alkyl), -SO2N(C1-6 alkyl)2, -CO2-(C1-6 alkyl), - NHCOCH2-phenyl, -OCH2- phenyl, -S02-phenyl, -NR3R4, phenyl, naphthyl, heteroaryl2, heterocyclyl2, -CO-heterocyclyl2 or C3-6 cycloalkyl; wherein each phenyl, naphthyl, heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally substituted, and wherein each phenyl, naphthyl, heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally fused to a 5- or 6-membered heteroaromatic or heterocyclic ring containing from 1 to 3 heteroatoms (selected from N, O and S); and wherein each heteroaryl2, heterocyclyl2 and C3-6 cycloalkyl group is optionally fused to a benzene ring; and pharmaceutically acceptable salts and solvates thereof. The compounds are useful as pharmaceuticals, particularly in the treatment of fibrotic diseases, cancer and pain.
Applicant(s) Inhibitaxin Limited
Representative Drug(s) D07UNH Drug Info IC50 = 2.59 nM [1]
Patent ID WO2016031987
Title Pyrimidinone Derivative Having Autotaxin-Inhibitory Activity.
Abstract A compound represented by any of formulas (Ia)-(Ic) or formula (II), or a pharmaceutically acceptable salt thereof. (In the formulas, R1, R2, R3, R4a, R4c, R5, R15, ring A, X1, and X2 are as defined in the specification.).
Applicant(s) National University University of Tokyo
Representative Drug(s) D03RAU Drug Info N.A. [1]
Patent ID WO2015175171
Title Substituted N-(2-(Amino)-2-Oxoethyl)Benzamide Inhibitors of Autotaxin and Their Preparation and Use In The Treatment of Lpa-Dependent or Lpa-Mediated Diseases.
Abstract The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
Applicant(s) X-Rx Discovery, Inc
Representative Drug(s) D00LWY Drug Info N.A. [1]
Patent ID WO2015163458
Title Aptamer for Bonding To Autotaxin and Inhibiting Biological Activity of Autotaxin, and Use for Same.
Abstract The present invention provides an aptamer that bonds to autotaxin, said aptamer including a nucleotide sequence represented by the formula GWAACAGGUUUUGCU (SEQ ID NO: 42) (in the formula, W is A or U, and uracil can be thymine), and being one of the following: (a) the aptamer, wherein in the nucleotide included in the aptamer, (i) the 2' position of the ribose in each pyrimidine nucleotide is a fluorine atom, and (ii) the 2' position of the ribose in each purine nucleotide is a hydroxy group; or (b) the aptamer from (a), wherein (i) the fluorine atoms at the 2' position of the ribose in each pyrimidine nucleotide are each independently unsubstituted or substituted with an atom or a group selected from the group consisting of a hydrogen atom, a hydroxy group, and a methoxy group, and (ii) the hydroxy groups at the 2' position of the ribose in each purine nucleotide are each independently unsubstituted or substituted with an atom or a group selected from the group consisting of a hydrogen atom, a methoxy group and a fluorine atom.
Applicant(s) Ribomic Inc
Patent ID WO2015154023
Title Substituted Spirocydic Inhibitors of Autotaxin.
Abstract The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
Applicant(s) X - Rx, Inc
Representative Drug(s) D0U8BD Drug Info N.A. [1]
Patent ID WO2015144609
Title Condensed [1,4]Diazepine Compounds As Autotaxin (Atx) and Lysophosphatidic Acid (Lpa) Production Inhibitors.
Abstract The invention provides novel compounds having the general formula (I) wherein R1, R2, A1 and A2 are as described herein, compositions including the compounds. These compounds of formula (I) are useful for therapy or prophylaxis in a mammal, and in particular to autotaxin (ATX) inhibitors which are inhibitors of lysophosphatidic acid (LPA) production and thus modulators of LPA levels and associated signaling, for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
Applicant(s) F. Hoffmann-La Roche Ag
Representative Drug(s) D0FM6Y Drug Info N.A. [1]
Patent ID WO2015129821
Title Fused Pyrazole Derivative Having Autotaxin Inhibitory Activity.
Abstract The present invention provides a compound that has an autotaxin inhibitory effect and is represented by formula (I) (in the formula, R1, R2, R3, R4a, R4b, R5a, and R5b are as defined in the description.), a medicine that uses said compound as an active component, and a treatment or prevention method for a disease involving autotaxin, said treatment or prevention method being characterized by the administration of said compound.
Applicant(s) National University University of Tokyo
Representative Drug(s) D07JTJ Drug Info N.A. [1]
Patent ID WO2014202458
Title Novel Compounds and Pharmaceutical Compositions Thereof for The Treatment of Inflammatory Disorders.
Abstract The present invention discloses compounds according to Formula I: Wherein R 1a, R 1b, R 2, R 4, R5, R 6, R 7, R 8, W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases,proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
Applicant(s) Galapagos Nv
Representative Drug(s) D0F1FD Drug Info N.A. [1]
Patent ID WO2014139978
Title New Octahydro-Pyrrolo[3,4-C]-Pyrrole Derivatives and Analogs Thereof As Autotaxin Inhibitors.
Abstract The invention provides novel compounds having the general formula (I) wherein R1, Y, A, W, R2, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds.
Applicant(s) Hoffmann La Roche
Representative Drug(s) D0E3ED Drug Info N.A. [1]
Patent ID WO2014139882
Title Compounds and Pharmaceutical Compositions Thereof for The Treatment of Inflammatory Disorders.
Abstract The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseasesby administering the compound of the invention.
Applicant(s) Galapagos Nv
Representative Drug(s) D0F1FD Drug Info N.A. [1]
Patent ID WO2014133112
Title 8-Substituted Imidazopyrimidinone Derivative Having Autotaxin Inhibitory Activity.
Abstract The present invention provides a compound represented by the formula (wherein the symbols are as defined in the description), which has an autotaxin inhibitory activity and a medicinal composition which contains the compound.
Applicant(s) National University University of Tokyo
Representative Drug(s) D09IKN Drug Info N.A. [1]
Patent ID WO2014025709
Title Compounds That Are S1P Modulating Agents and/or Atx Modulating Agents.
Abstract Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
Applicant(s) Biogen Idec Ma Inc
Representative Drug(s) D0S8EH Drug Info N.A. [1]
Patent ID WO2014025708
Title Compounds That Are S1P Modulating Agents and/or Atx Modulating Agents.
Abstract Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
Applicant(s) Biogen Idec Ma Inc
Representative Drug(s) D0S8EH Drug Info N.A. [1]
Patent ID WO2014018891
Title Compounds That Are S1P Modulating Agents and/or Atx Modulating Agents.
Abstract Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).
Applicant(s) Biogen Idec Ma Inc
Representative Drug(s) D0S8EH Drug Info N.A. [1]
Patent ID WO2014018887
Title Atx Modulating Agents.
Abstract Compounds of formula (I) can modulate the activity of autotaxin (ATX).
Applicant(s) Biogen Idec Ma Inc
Representative Drug(s) D0WX7F Drug Info N.A. [1]
Patent ID WO2014018881
Title Atx Modulating Agents.
Abstract Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
Applicant(s) Biogen Idec Ma Inc
Representative Drug(s) D0WX7F Drug Info N.A. [1]
Patent ID WO2013138241
Title Human Autotaxin Antibodies and Methods of Use.
Abstract Antibodies and compositions capable of binding and, in a particular aspect, inhibiting the lysophosphatidylipase D activity of human autotaxin protein. The antibodies or are useful in detecting human autotaxin protein and treating diseases and disorders associated with unwanted lysophosphatidylipase D and the presence of lysophosphatidic acid, such as cancer and pulmonary diseases.
Applicant(s) Janssen Biotech, Inc
Patent ID WO2012127885
Title Tetrahydrocarboline Derivative.
Abstract The invention addresses the problem of providing a drug with inhibitory activity against ENPP2, which is a different target from prior drugs, as a pharmaceutical product that is useful in patients with urinary retention in whom the efficacy of previous drugs was unsatisfactory. The present invention provides a compound represented by formula (I) that has ENPP2-inhibiting activity (in the formula, the definitions of the various groups are the same as described in the Specifications), a salt or solvate thereof, a prodrug thereof, and an agent for preventing, treating and/or mitigating the symptoms of urinary retention containing same as an active ingredient.
Applicant(s) Ono Pharmaceutical Co., Ltd
Representative Drug(s) D00PJE Drug Info N.A. [1]
Patent ID WO2012005227
Title Tetrahydrocarboline Derivative.
Abstract As a pharmaceutical product useful for patients with urine evacuation disorders for whom conventional drugs are ineffective, a drug is disclosed having inhibitory activity on ENPP2, which is a target different from that of already existing drugs. Disclosed are a compound represented by formula (I) (wherein definitions of the groups are as in the description) having ENPP2 inhibitory activity, a salt or solvate thereof, a prodrug of either of these, or an agent for prevention, treatment and/or symptomatic improvement of urine evacuation disorders containing either of these as an active ingredient.
Applicant(s) Ono Pharmaceutical Co., Ltd
Representative Drug(s) D0RB6K Drug Info N.A. [1]
Patent ID WO2016028686
Title Methods and Compositions for The Treatment of Metabolic Disorders.
Abstract Described herein are methods and compositions for treatment or prevention of metabolic disorder(s) in an individual. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound. The autotaxin-lysophosphatidic acid signaling pathway has been implicated in a variety of signaling pathways involved in cell migration, proliferation, and survival. Due to its role in thes pathways, autotaxin has been explored in the last decade as a drug discovery target for the treatment of chronic inflammation, neuropathi pain, fibrotic disease, and various cancers. Intensive efforts have focused on identifying autotaxin inhibitors in the treatment of these disorders.
Applicant(s) Pharmakea, Inc
Patent ID WO2015147290
Title Aptamer Inhibiting Biological Activity of Autotaxin By Binding with Autotaxin, and Use Thereof.
Abstract The present invention provides an aptamer that comprises the nucleotide sequence represented by formula (I): CGGAACC-N1-GGTC (I) (in the formula, N1 is 3 to 11 arbitrary nucleotides) and that binds wi.
Applicant(s) Ribomic Inc
Patent ID WO2015144605
Title Bicyclic Compounds As Autotaxin (Atx) and Lysophosphatidic Acid (Lpa) Production Inhibitors.
Abstract The invention provides novel compounds having the general formula (I) wherein R1, R2, A, W, m, n, p and q are as described herein, compositions including the compounds. The compounds of formula (I) are useful as autotaxin (ATX) inhibitors which are inhibitors of lysophosphatidic acid (LPA) production and thus modulators of LPA levels and associated signaling; in particular they are useful for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
Applicant(s) F. Hoffmann-La Roche Ag
Patent ID WO2015077503
Title Autotaxin Inhibitor Compounds.
Abstract Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
Applicant(s) Pharmakea, Inc
Patent ID WO2015048301
Title Autotaxin Inhibitor Compounds.
Abstract Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
Applicant(s) Pharmakea, Inc
Patent ID WO2015042053
Title Vinyl Autotaxin Inhibitor Compounds.
Abstract Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
Applicant(s) Pharmakea, Inc
Patent ID WO2014143583
Title Imidazo Pyridine Compounds.
Abstract The present invention provides compounds of the formula I, wherein X is a bond or CH2; Q is CH2 or O; L is selected from the group consisting of -OCH2- and -CH2O-; or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors.
Applicant(s) Eli Lilly and Company
Patent ID WO2014048865
Title New Bicyclic Derivatives.
Abstract The invention provides novel compounds having the general formula (I) wherein R1, Y, A, W, R2, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds.
Applicant(s) F. Hoffmann-La Roche Ag
Patent ID WO2010115491
Title Piperidine and Piperazine Derivatives As Autotaxin Inhibitors.
Abstract The present invention relates to piperidine and pyrazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
Applicant(s) Merck Patent Gmbh
Patent ID WO2010112116
Title Heterocyclic Compounds As Autotaxin Inhibitors.
Abstract The invention relates to compounds of the formula I, where Het, R, X, Y, R1, and p have the meanings given in Claim 1, wherein said compounds are autotaxin inhibitors and can be used for treating tumors.
Applicant(s) Merck Patent Gmbh
Patent ID WO2009046841
Title Piperidine and Piperazine Derivatives for Treating Tumours.
Abstract The invention relates to compounds of formula (I), in which R1, R2, R3, D, G, Q and W are defined as cited in claim (1). Said compounds can be used for treating tumours.
Applicant(s) Merck Patent Gmbh
United States Patent and Trademark Office (USPTO)
Patent ID US2014171403
Title Autotaxin Inhibitors.
Representative Drug(s) D0J5GC Drug Info N.A. Click to Show More [1]
2 D0NG8Q Drug Info N.A. [1]
References  Top
REF 1 Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.